 |
 |
|
||||||||||||||||||||||||
| A PUBLICATION OF CME OUTFITTERS | VOLUME 1, ISSUE 27, November 21, 2006 | |||||||||||||||||||||||||
 |
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
| FROM THE CLINICAL KNOWLEDGE CENTER Assessing Evidence-Based Treatments for Schizophrenia and Bipolar Disorder AThe management of schizophrenia and bipolar disorder—two chronic, debilitating psychiatric disorders—is frequently complicated by real-world challenges such as nonadherence to medications. Treatment adherence can be determined in part by medication efficacy and side effects. Atypical antipsychotics are the recommended first-line therapy for the treatment of schizophrenia, and recent clinical evidence indicates that atypical antipsychotics in combination with mood stabilizers may also provide effective management of bipolar mania. While atypical antipsychotics are a useful tool in the arsenal to manage schizophrenia and bipolar disorder, they are not without limitations. As a class, atypical agents are associated with side effects such as weight gain and dysregulation of glucose and lipids—all of which can increase the risk of heart disease and metabolic syndrome and decrease treatment adherence. You are invited to join John Kane, MD, and Paul Keck, Jr., MD, in an interactive audioconference to learn how clinicians can utilize evidence-based strategies to manage schizophrenia and bipolar disorder and improve patient outcomes without compromising patient safety or treatment adherence. Click HERE to register. Resources Citrome L, Goldberg JG, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 2005;13:28-42. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651. Practice guideline for the treatment of schizophrenia, 2nd edition. American Psychiatric Association, Feb 2004. Newcomer JW. Second-generation atypical antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93. Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv 2004;55:264-269. |
||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||
| ©2006 CME Outfitters, LLC |
||||||||||||||||||||||||||